R&D channel feed – Endpoints News

R&D channel feed

Meet Ike, the drug test subject that lived to be 140

9 years ago

Still in spotlight of a federal probe, Insys touts PhIII pain study as it preps an NDA

9 years ago

AstraZeneca sells off more assets from its island of misfit drugs in $1.6B Pfizer deal

9 years ago

Clovis soars as its PARP drug rucaparib lines up for FDA review with positive data

9 years ago

Gilead tackles a big PhIII program for blockbuster hopeful filgotinib

9 years ago

Tokai retreats from the clinic after lead drug implodes in PhIII

9 years ago

Backed by a biotech legend, two young entrepreneurs tackle one of the Holy Grails of R&D

9 years ago

Little Stemline grabs a big ‘breakthrough’ title for its pivotal-stage cancer drug

9 years ago

Sanofi can’t even buy a break now, as rival Novo speeds ahead on diabetes showdown

9 years ago

Axel Bouchon starts signing players for a new league of game-changing biotechs

9 years ago

Pfizer bags Medivation buyout with blowout $14B cash offer

9 years ago

Golden Triangle gets £75M in fresh venture funds for Cambridge U spinouts

9 years ago

Welcome Casebia, the $335M gene editing JV hatched by Bayer and CRISPR Therapeutics

9 years ago

Following another PhII failure, cash-strapped Cerulean chops half its staff

9 years ago

Protocols: Mallinckrodt lands a new corporate campus in NJ; Nutrinia bags a $30M round for oral insulin

9 years ago

Auris shares are crushed as tinnitus drug fails PhIII test

9 years ago

Expanded syndicate puts Avelas onto the PoC track with $20M cancer tech round

9 years ago

Cerulean crashes after lead nano drug flubs its second PhII cancer study

9 years ago

Protocols: Indivior claims PhIII success, points to 2017 FDA OK; InVivo touts another patient response in spinal study

9 years ago

Controversial patient deaths in CAR-T study spur a class action suit against Juno

9 years ago

RIP: After burning through $463M, StemCells’ corpse is bought out for the public shell

9 years ago

The $140,672,343 man: Why does Brent Saunders have the richest golden parachute in biopharma?

9 years ago

Split the pot? Radius shows its osteoporosis cards in final blockbuster match with Amgen

9 years ago

The ‘don’t eat me’ antidote: GlaxoSmithKline, Roche and Novo back $86M startup in high-stakes CD47 showdown

9 years ago

First page Previous page 325 326 327328329 330 331 Next page Last page